SciSparc Ltd. SPRC
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- -98.40%
- 1 year
- -99.08%
5D -0.1718 (-48.24%)
- Market cap
- 481.60K
- Revenue (ttm)
- 1.75M
- EPS (ttm)
- 248.24
- Shares out
- 10.36M
- P/E ratio
- 0.00
- YTD return
- -98.40%
- 1-year return
- -99.08%
- Volume
- 4.55M
- Avg volume
- 2.86M
- Open
- 0.257
- Previous close
- 0.30
- Day's range
- 0.167 – 0.2623
- 52-week range
- 0.167 – 29.88
- Beta
- 1.04
Key statistics
- 50-day average
- 0.23526
- 200-day average
- 0.77116
- Enterprise value
- 4.92K
- Price / sales
- 1.38
- Price / book
- 0.12
- Revenue growth
- -57.40%
- Free cash flow
- -3.97M
- Total cash
- 2.56M
- Total debt
- 64.00K
- Return on equity
- -85.91%
- Short % of float
- 0.93%
Fundamental scorecard
11 of 25 checks passed on SPRC’s reported financials
11of 25 checks passed
- Value 4 of 5
- Growth 1 of 5
- Profitability 4 of 5
- Financial health 2 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Financials — quick view
About SciSparc Ltd.
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- scisparc.com
News
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
Why Gap Shares Are Trading Higher By Around 4%; Here Are 20 Stocks Moving Premarket
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Why Palo Alto Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
SciSparc (SPRC) Stock Jumps 39% After Hours as Agentic AI Strategy Draws Attention
SciSparc: Former National Security Advisor to Prime Minister Benjamin Netanyahu Renowned AI Prof. Jacob Nagel Joins the Company's SAB
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Your note
Sign in to keep a note on SPRC — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| UBS Group AG | 0.67% | 69,006 | 16.06K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.36% | 37,082 | 8.63K | Sep 29, 2024 |
| Virtu Financial LLC | 0.14% | 14,106 | 3.28K | Sep 29, 2024 |
| Rhumbline Advisers | 0.03% | 3,464 | 806 | Sep 29, 2024 |
| Morgan Stanley | 0.00% | 238 | 55 | Sep 29, 2024 |
